Business_Travel
Matthew Raybould
About The Speaker
Matthew Raybould
Dr. Matthew Raybould holds an MChem in Chemistry and a DPhil in Immunoinformatics from the University of Oxford. His doctorate focused on the development of 3D structure-aware computational tools for antibody drug discovery and development, and was conducted in the Oxford Protein Informatics Group (OPIG) under the supervision of Professor Charlotte Deane. Matthew continues to work at Oxford as a senior postdoctoral researcher, performing and supervising computational analyses of adaptive immune receptor repertoires and methodology development for in silico-assisted immunotherapy/vaccine design.
An ecosystem of tools for computational antibody design, including the second-generation Therapeutic Antibody Profiler
Computational technologies that assist in antibody design and discovery are increasingly contributing towards drug development. In this talk, I will present an overview of the Oxford Protein Informatics Group’s suite of tools for computational antibody design, with a focus on our latest work on in silico developability risk prediction. This will cover the integration of machine learning-based structure prediction into our Therapeutic Antibody Profiler (“TAP2”), examples where TAP2 could be used to guide molecular derisking or library design, and outstanding challenges.